AS-OCT produces better results after long-term dark adaptation

Article

A study announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.

A paper published in the Journal of Glaucoma has announced the increased reliability of anterior-segment optical coherence tomography (AS-OCT) when used on patients after long-term dark adaptation.

Dr Dejiao Li et al., Optoelectronics Research Centre, University of Southampton, Hampshire, UK, split 110 participants into 2 groups a study group and a control group. In the study group there were 70 suspects of primary angle closure and in the control group there were 40 normal participants. AS-OCT was used to measure the anterior chamber angle configuration and pupil diameter at both 3 minutes and 1.5 hours of dark adaptation.

The study group presented a significantly higher mean number of closed angle segments at 3 minutes of dark adaptation compared to 1.5 hours of dark adaptation or light conditions.

Pupil diameter was linked to the number of closed angle segments at 3 minutes of dark adaptation. Final intraocular pressure demonstrated an improved correlation with angle configuration segments at 3 minutes compared to 1.5 hours.

Overall, the dark room test with AS-OCT at 3 minutes was positive in a significantly high number of patients compared to dark room adaptation at 1.5 hours. The treatment was heavily advised as a method to identify glaucoma suspects.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
EURETINA 2025: Boris Stanzel, MD, methotrexate is rocking the European retina landscape
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
© 2025 MJH Life Sciences

All rights reserved.